Skip to content

Citius Oncology, Inc.: 10-Q filed 2024-08-09

What Citius Oncology, Inc. reported in its quarterly report filed 2024-08-09 (fiscal Q2 2024): 18 published measures, 57 facts as tagged in accession 0001493152-24-030991.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-09
Fiscal period
fiscal Q2 2024
Accession
0001493152-24-030991 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Oncology, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-3049,193,627USD
At 2023-12-3172,623,594USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-3,039,950USD
At 2024-03-31-2,455,991USD
At 2023-12-31-1,987,562USD
At 2023-06-30-1,968USD
At 2023-03-31197,586USD
At 2022-12-31345,508USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30252,462USD91
2024-01-01 to 2024-06-30742,291USD182
2024-01-01 to 2024-03-31489,829USD91
2023-04-01 to 2023-06-30616,296USD91
2023-01-01 to 2023-06-301,228,021USD181
2023-01-01 to 2023-03-31611,725USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-557,796USD182
2023-01-01 to 2023-06-30-269,055USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-24,282,122USD182
2023-01-01 to 2023-06-30349,975USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-06-3024,807,433USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-3,040,117USD
At 2023-12-31-1,987,729USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-304,312,077shares91
2024-01-01 to 2024-06-304,525,784shares182
2023-04-01 to 2023-06-306,600,000shares91
2023-01-01 to 2023-06-306,600,000shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-304,312,077shares91
2024-01-01 to 2024-06-304,525,784shares182
2023-04-01 to 2023-06-306,600,000shares91
2023-01-01 to 2023-06-306,600,000shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-300.04USD/shares91
2024-01-01 to 2024-06-300.11USD/shares182
2023-04-01 to 2023-06-300.07USD/shares91
2023-01-01 to 2023-06-300.14USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-300.04USD/shares91
2024-01-01 to 2024-06-300.11USD/shares182
2023-04-01 to 2023-06-300.07USD/shares91
2023-01-01 to 2023-06-300.14USD/shares181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-383,957USD91
2024-01-01 to 2024-06-30-652,386USD182
2023-04-01 to 2023-06-30-199,554USD91
2023-01-01 to 2023-06-30-347,476USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-3040,988USD
At 2023-12-3158,200USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-303,080,938USD
At 2023-12-312,045,762USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-302,341,000shares
At 2023-12-312,341,000shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-06-30485,750USD
At 2023-12-31375,886USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30383,957USD91
2024-01-01 to 2024-06-30652,386USD182
2023-04-01 to 2023-06-30199,554USD91
2023-01-01 to 2023-06-30347,476USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-04-01 to 2024-06-30636,419USD91
2024-01-01 to 2024-06-301,394,677USD182
2023-04-01 to 2023-06-30815,850USD91
2023-01-01 to 2023-06-301,575,497USD181

Inspect the source

Entity
Citius Oncology, Inc. / CIK 0001851484
Captured
2026-09-21T17:32:34.031Z
SEC response SHA-256
1e8c39a029a9529c1971ba7b07551c1ef4dd6de443d807231887851f2cef037a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001851484.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))